{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:43:22Z","timestamp":1792503802506,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psychedelic-assisted therapy (PAT) is increasingly discussed as a potential intervention for anxiety, depression, and existential distress among patients with advanced cancer. Yet the ethical challenges of PAT for patients approaching the end of life remain underdeveloped, particularly for oncologists who may be asked to counsel patients or consider referral to clinical trials. This article uses 3 deidentified clinical vignettes from a clinical trial of psilocybin-assisted therapy in a palliative oncology context to examine what it means for PAT to \u201cwork.\u201d We argue that PAT should not be evaluated only by symptom reduction or the production of mystical experiences, but also by whether it helps patients move toward valued forms of self-understanding, connection, courage, acceptance, or reconciliation. Drawing on the concept of \u201caspirational autonomy,\u201d we propose that meaningful consent to PAT need not depend on full foreknowledge of an unpredictable experience. Rather, consent may be understood as a patient\u2019s endorsement of a supported process of moral and existential aspiration. We then identify practical ethical challenges for oncology, including expectation management, therapeutic ambiguity, somatic amplification, limited time for integration, and family dynamics. We conclude by offering candidate-selection considerations for oncologists, emphasizing aspirational clarity, cognitive and psychological stability, temporal feasibility, relational support, and realistic expectations.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag402","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:53:33Z","timestamp":1792065213000},"source":"Crossref","is-referenced-by-count":0,"title":["Aspirational autonomy and psychedelic-assisted therapy in advanced cancer: ethical lessons from clinical cases"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3311-1503","authenticated-orcid":false,"given":"Keenan Wills","family":"Davis","sequence":"first","affiliation":[{"name":"Emory University School of Medicine, Emory University , Atlanta, GA 30322,","place":["United States"]},{"name":"Emory Center for Psychedelics and Spirituality, Emory University , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2342-5242","authenticated-orcid":false,"given":"Michelle C","family":"Bach","sequence":"additional","affiliation":[{"name":"Emory Center for Psychedelics and Spirituality, Emory University , Atlanta, GA 30322,","place":["United States"]},{"name":"Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Emory University , Atlanta, GA 30322,","place":["United States"]},{"name":"Emory Center for Ethics, Emory University , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5785-7473","authenticated-orcid":false,"given":"JoEllen","family":"Schimmels","sequence":"additional","affiliation":[{"name":"Nell Hodgson Woodruff School of Nursing, Emory University , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0079-2250","authenticated-orcid":false,"given":"Ali John","family":"Zarrabi","sequence":"additional","affiliation":[{"name":"Emory Center for Psychedelics and Spirituality, Emory University , Atlanta, GA 30322,","place":["United States"]},{"name":"Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Emory University , Atlanta, GA 30322,","place":["United States"]},{"name":"Division of Palliative Medicine, Emory University School of Medicine, Emory University , Atlanta, GA 30322,","place":["United States"]},{"name":"Department of Family and Preventive Medicine, Emory University School of Medicine, Emory University , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"2026102009175706300_oyag402-B1","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jpainsymman.2010.05.010","article-title":"Existential suffering in the palliative care setting: an integrated literature review","volume":"41","author":"Boston","year":"2011","journal-title":"J Pain Symptom Manage"},{"key":"2026102009175706300_oyag402-B2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/7854_2021_278","article-title":"The potential of psychedelics for end of life and palliative care","volume":"56","author":"Yaden","year":"2022","journal-title":"Curr Top Behav Neurosci"},{"key":"2026102009175706300_oyag402-B3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"2026102009175706300_oyag402-B4","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"2026102009175706300_oyag402-B5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"2026102009175706300_oyag402-B6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J Psychopharmacol"},{"key":"2026102009175706300_oyag402-B7","doi-asserted-by":"publisher","first-page":"CD015383","DOI":"10.1002\/14651858.CD015383.pub2","article-title":"Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases","volume":"9","author":"Schipper","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102009175706300_oyag402-B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/02692163251383335","article-title":"Psilocybin-assisted therapy for individuals with palliative care needs: a systematic review of safety and efficacy","volume":"40","author":"Matos","year":"2026","journal-title":"Palliat Med"},{"key":"2026102009175706300_oyag402-B9","author":"Noorani","year":"2020"},{"key":"2026102009175706300_oyag402-B10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamapsychiatry.2022.2546","article-title":"Preparing for the bursting of the psychedelic hype bubble","volume":"79","author":"Yaden","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"2026102009175706300_oyag402-B11","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.21037\/apm-24-35","article-title":"Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review","volume":"13","author":"Kim","year":"2024","journal-title":"Ann Palliat Med"},{"key":"2026102009175706300_oyag402-B12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s42843-025-00145-3","article-title":"Meaning and purpose therapy modified for psilocybin (P-MaP): a treatment model for palliative care patients","volume":"51","author":"Garrity","year":"2025","journal-title":"J Health Serv Psychol"},{"key":"2026102009175706300_oyag402-B13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"key":"2026102009175706300_oyag402-B14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/pmr.2024.0108","article-title":"Roadmap for equitable access and responsible use of psilocybin-assisted psychotherapy in palliative care","volume":"6","author":"Dorval","year":"2025","journal-title":"Palliat Med Rep"},{"key":"2026102009175706300_oyag402-B15","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.3390\/healthcare13182275","article-title":"Psychedelic-assisted therapy in palliative care-insights from an international workshop","volume":"13","author":"Schuldt","year":"2025","journal-title":"Healthcare (Basel)"},{"key":"2026102009175706300_oyag402-B16","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780198717959.001.0001","volume-title":"Transformative Experience","author":"Paul","year":"2014"},{"key":"2026102009175706300_oyag402-B17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fnhum.2016.00269","article-title":"Ego-dissolution and psychedelics: validation of the ego-dissolution inventory","volume":"10","author":"Nour","year":"2016","journal-title":"Front Hum Neurosci"},{"key":"2026102009175706300_oyag402-B18","doi-asserted-by":"publisher","first-page":"1108333","DOI":"10.3389\/fpsyg.2023.1108333","article-title":"Transformative experience and informed consent to psychedelic-assisted psychotherapy","volume":"14","author":"Jacobs","year":"2023","journal-title":"Front Psychol"},{"key":"2026102009175706300_oyag402-B19","volume-title":"Principles of Biomedical Ethics","author":"Beauchamp","year":"2019","edition":"8th ed"},{"key":"2026102009175706300_oyag402-B20","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780190639488.001.0001","volume-title":"Aspiration: The Agency of Becoming","author":"Callard","year":"2018"},{"key":"2026102009175706300_oyag402-B21","volume-title":"Aspiring to Autonomy: An Ethical Phenomenology of DBS for Depression","author":"Davis","year":"2023"},{"key":"2026102009175706300_oyag402-B22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jpainsymman.2006.09.014","article-title":"Healing connections: on moving from suffering to a sense of well-being","volume":"33","author":"Mount","year":"2007","journal-title":"J Pain Symptom Manage"},{"key":"2026102009175706300_oyag402-B23","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1016\/j.jpainsymman.2025.10.015","article-title":"Meaning and psychedelics in palliative care: a narrative review","volume":"71","author":"Alexander","year":"2026","journal-title":"J Pain Symptom Manage"},{"key":"2026102009175706300_oyag402-B24","doi-asserted-by":"publisher","DOI":"10.64898\/2026.07.11.26357570","article-title":"Psilocybin-assisted early palliative care for demoralization and chronic pain: an open-label pilot study","author":"Zarrabi","year":"2026","journal-title":"medRxiv"},{"key":"2026102009175706300_oyag402-B25","author":"ClinicalTrials.gov","year":"2026"},{"key":"2026102009175706300_oyag402-B26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1353\/pbm.2024.a919717","article-title":"Valuing the acute subjective experience","volume":"67","author":"Cheung","year":"2024","journal-title":"Perspect Biol Med"},{"key":"2026102009175706300_oyag402-B27","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J Psychopharmacol"},{"key":"2026102009175706300_oyag402-B28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1556\/2054.2022.00232","article-title":"Psychedelic integration challenges: participant experiences after a psilocybin truffle retreat in The Netherlands","volume":"6","author":"Lutkajtis","year":"2023","journal-title":"J Psychedelic Stud"},{"key":"2026102009175706300_oyag402-B29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12152-024-09545-6","article-title":"Giving consent to the ineffable","volume":"17","author":"Villiger","year":"2024","journal-title":"Neuroethics"},{"key":"2026102009175706300_oyag402-B30","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamapsychiatry.2024.0184","article-title":"Essentials of informed consent to psychedelic medicine","volume":"81","author":"Marks","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"2026102009175706300_oyag402-B31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/07067437231225937","article-title":"Informed consent to psychedelic-assisted psychotherapy: ethical considerations","volume":"69","author":"Lee","year":"2024","journal-title":"Can J Psychiatry"},{"key":"2026102009175706300_oyag402-B32","doi-asserted-by":"publisher","first-page":"17493","DOI":"10.1038\/s41598-026-48084-3","article-title":"Major life changes following psychedelic use: a retrospective survey among people using psychedelics naturalistically","volume":"16","author":"Aday","year":"2026","journal-title":"Sci Rep"},{"key":"2026102009175706300_oyag402-B33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0160-2527(82)90026-7","article-title":"The therapeutic misconception: informed consent in psychiatric research","volume":"5","author":"Appelbaum","year":"1982","journal-title":"Int J Law Psychiatry"},{"key":"2026102009175706300_oyag402-B34","volume-title":"Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life","author":"Institute of Medicine","year":"2015"},{"key":"2026102009175706300_oyag402-B35","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMcp074045","article-title":"Assessment of patients\u2019 competence to consent to treatment","volume":"357","author":"Appelbaum","year":"2007","journal-title":"N Engl J Med"},{"key":"2026102009175706300_oyag402-B36","volume-title":"LSD Psychotherapy","author":"Grof","year":"1980"},{"key":"2026102009175706300_oyag402-B37","doi-asserted-by":"publisher","first-page":"e70586","DOI":"10.1002\/cam4.70586","article-title":"Psychedelics for cancer pain and associated psychological distress: a narrative review of a potential strategy","volume":"14","author":"Belitzky","year":"2025","journal-title":"Cancer Med"},{"key":"2026102009175706300_oyag402-B38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/02791072.1997.10400190","article-title":"Set, setting, and matrix","volume":"29","author":"Eisner","year":"1997","journal-title":"J Psychoactive Drugs"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag402\/71989997\/oyag402.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag402\/71989997\/oyag402.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag402\/71989997\/oyag402.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:18:03Z","timestamp":1792502283000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag402\/8923635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag402","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,7]]},"article-number":"oyag402"}}